Injectables & Product Suppliers

Most established med spas carry both. Patients have real brand preferences—some ask for Botox by name, others respond better to Dysport or want Sculptra—and carrying two houses lets you serve them all while keeping each rep's pricing honest. The strategic decision isn't either/or; it's which house anchors your account. Your anchor is where you concentrate volume to hit rebate tiers, whose loyalty program you enroll patients in by default, and whose portfolio bundling sets your economics. Pick the anchor by patient demand and treatment mix, then keep the other as a strong second account.

Allē (Allergan) is the larger network by a wide margin—roughly 6 million consumer members across some 19,000 practices—earning points on Botox, Juvéderm, and SkinMedica and nudging members to rebook at participating practices. ASPIRE Galderma Rewards plays the same role across Dysport, Restylane, and Sculptra with points, promotions, and practice-level benefits. Both combine consumer retention rails with rebates that lower your effective product cost. Allē's scale gives it more gravitational pull with brand-driven patients; ASPIRE's advantage is breadth across Galderma's wider portfolio, including the biostimulator category Allergan doesn't cover.

Both are well-established, FDA-approved neurotoxins with long clinical track records, and experienced injectors get excellent results with either; onset, spread, and dosing conversions differ, so injector familiarity matters. Commercially, Botox carries far more unprompted consumer demand, while Dysport is frequently positioned at a sharper effective price per treatment once rep-negotiated wholesale and ASPIRE benefits are factored in. All injectable pricing is negotiated account by account, so compare the effective per-treatment economics with your own reps rather than relying on list-price assumptions.

The headline gap is Sculptra, Galderma's poly-L-lactic-acid biostimulator, which anchors the fast-growing regenerative and natural-results category—Allergan has no direct equivalent. Galderma also brings Alastin, a channel-protected, procedure-focused skincare line, alongside Restylane's broad filler family, so a single Galderma account can cover toxin, filler, biostimulator, and skincare. Allergan's counterweights are Botox's unmatched name-brand demand, the Juvéderm franchise, SkinMedica skincare, and Allē's larger loyalty network. Which matters more depends on whether your patient base skews brand-driven or regenerative.

No. Both companies sell only through direct accounts and authorized distributors, and both require ordering under an appropriately licensed prescriber. Deeply discounted product from grey-market importers is how counterfeit and unapproved toxin reaches patients—the FDA's counterfeit-Botox enforcement, including 18 warning letters to distributors in November 2025, underlines the risk. Buying outside authorized channels can void product support, expose your license and insurance, and endanger patients. Register your account directly with each manufacturer, keep purchase records, and treat too-good-to-be-true pricing as a red flag.